Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(S6):1–158.
Article
Google Scholar
National Center for Health Statistics. Centers for Diseases Control and Prevention. Mortality statistics. https://www.cdc.gov/nchs/nvss/deaths.htm. Accessed 25 February 2020.
Berntorp E, Shapiro AD. Modern haemophilia care. Lancet. 2012;379(9824):1447–56.
Article
Google Scholar
Osooli M, Lövdahl S, Steen Carlsson K, et al. Comparative burden of arthropathy inmild haemophilia: a register-based study in Sweden. Haemophilia. 2017;23(2):e79–86.
Article
CAS
Google Scholar
Peerlinck K, Jacquemin M. Mild haemophilia: a disease with many faces and many unexpected pitfalls. Haemophilia. 2010;16(Suppl 5):100–6.
Article
Google Scholar
Soucie JM, Grosse SD, Siddiqi A-E-A, et al. The effects of joint disease, inhibitors and other complications on health-related quality of life among males with severe haemophilia A in the United States. Haemophilia. 2017;23(4):e287–93.
Article
CAS
Google Scholar
Soucie JM, Monahan PE, Kulkarni R, et al. The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B. Blood Adv. 2018;2(16):2136–44.
Article
Google Scholar
Warren BB, Thornhill D, Stein J, et al. Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study. Blood Adv. 2020;4(11):2451–9.
Article
Google Scholar
Fischer K, Valentino L, Ljung R, Blanchette V. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors. Haemophilia. 2008;14(Suppl 3):196–201.
Article
Google Scholar
O’Hara J, Sima CS, Frimpter J, et al. Long-term outcomes from prophylactic or episodic treatment of haemophilia A: a systematic review. Haemophilia. 2018;24(5):e301–11.
Article
Google Scholar
Mason JA, Parikh S, Tran H, Rowell J, McRae S. Australian multicentre study of current real-world prophylaxis practice in severe and moderate haemophilia A and B. Haemophilia. 2018;24(2):253–60.
Article
CAS
Google Scholar
Gringeri A, Mantovani L, Mackensen SV. Quality of life assessment in clinical practice in haemophilia treatment. Haemophilia. 2006;12(Suppl 3):22–9.
Article
Google Scholar
Holstein K, van Mackensen S, Bokemeyer C, Langer F. The impact of bleeding disorders on the socioeconomic status of adult patients. Hamostaseologie. 2018;38(3):150–7.
PubMed
Google Scholar
O’Hara J, Walsh S, Camp C, et al. The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. Health Qual Life Outcomes. 2018;16(1):84.
Article
Google Scholar
Cavazza M, Kodra Y, Armeni P, et al. Social/economic costs and quality of life in patients with haemophilia in Europe. Eur J Health Econ. 2016;17(Suppl 1):53–65.
Article
Google Scholar
Kodra Y, Cavazza M, Schieppati A, et al. The social burden and quality of life of patients with haemophilia in Italy. Blood Transfus. 2014;12(Suppl 3):s567–75.
PubMed
PubMed Central
Google Scholar
Castaman G. The benefits of prophylaxis in patients with hemophilia B. Expert Rev Hematol. 2018;11(8):673–83.
Article
CAS
Google Scholar
Fischer K, Lewandowski D, Janssen MP. Modelling lifelong effects of different prophylactic treatment strategies for severe haemophilia A. Haemophilia. 2016;22(5):e375–82.
Article
CAS
Google Scholar
Malec LM, Cheng D, Witmer CM, et al. The impact of extended half-life factor concentrates on prophylaxis for severe hemophilia in the United States. Am J Hematol. 2020;95(8):960–5.
Article
Google Scholar
Manco-Johnson MJ, Lundin B, Funk S, et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. J Thromb Haemost. 2017;15(11):2115–24.
Article
CAS
Google Scholar
Darby SC, Kan SW, Spooner RJ, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood. 2007;110(3):815–25.
Article
CAS
Google Scholar
Schrijvers LH, Beijlevelt-van der Zande M, Peters M, et al. Adherence to prophylaxis and bleeding outcome in haemophilia: a multicentre study. Br J Haematol. 2016;174(3):454–60.
Article
Google Scholar
Thornburg CD, Duncan NA. Treatment adherence in hemophilia. Patient Prefer Adher. 2017;11:1677.
Article
Google Scholar
Escobar M, Santagostino E, Mancuso ME, et al. Switching patients in the age of long-acting recombinant products? Expert Rev Hematol. 2019;12(Suppl 1):1–13.
Article
CAS
Google Scholar
Lambert T, Benson G, Dolan G, et al. Practical aspects of extended half-life products for the treatment of haemophilia. Ther Adv Hematol. 2018;9(9):295–308.
Article
CAS
Google Scholar
Tortella BJ, Alvir J, McDonald M, et al. Real-world analysis of dispensed IUs of coagulation factor IX and resultant expenditures in hemophilia B patients receiving standard half-life versus extended half-life products and those switching from standard half-life to extended half-life products. J Manag Care Spec Pharm. 2018;24(7):643–53.
PubMed
Google Scholar
Chen CX, Baker JR, Nichol MB. Economic burden of illness among persons with hemophilia B from HUGS Vb: examining the association of severity and treatment regimens with costs and annual bleed rates. Value Health. 2017;20(8):1074–82.
Article
Google Scholar
Li N, Sawyer EK, Maruszczyk K, et al. Economic burden of hemophilia B in the US: a systematic literature review. J Drug Assess. 2019;8(Suppl 1):28.
Article
Google Scholar
Cutter S, Molter D, Dunn S, et al. Impact of mild to severe hemophilia on education and work by US men, women, and caregivers of children with hemophilia B: The Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B-HERO-S) study. Eur J Haematol. 2017;98(Suppl 86):18–24.
Article
Google Scholar
O’Hara J, Hughes D, Camp C, et al. The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Dis. 2017;12(1):106.
Article
Google Scholar
Foppen W, van der Schaff IC, Beek FJA, Mali WPTM, Fischer K. MRI predicts 5-year joint bleeding and development of arthropathy on radiographs in hemophilia. Blood Adv. 2020;4(1):113–21.
Article
Google Scholar
Berntorp E, Dolan G, Hay C. European retrospective study of real-life haemophilia treatment. Haemophilia. 2017;23(1):105–14.
Article
CAS
Google Scholar
Bérubé S, Cloutier-Bergeron A, Amesse C, Sultan S. Understanding adherence to treatment and physical activity in children with hemophilia: the role of psychosocial factors. Pediatr Hematol Oncol. 2017;34(1):1–9.
Article
Google Scholar
Di Minno G, Santagostino E, Morfini M, et al. Attempting to remedy sub-optimal medication adherence in haemophilia: the rationale for repeated ultrasound visualisations of the patient’s joint status. Patient Prefer Adher. 2019;13:233–40.
Article
Google Scholar
United States Food and Drug Administration. Public meeting on patient-focused drug development for hemophilia A, hemophilia B, von Willebrand disease and other heritable bleeding disorders. https://www.federalregister.gov/documents/2014/07/09/2014-15990/public-meeting-on-patient-focused-drug-development-for-hemophilia-a-hemophilia-b-von-willebrand. Accessed 13 October 2020.
Martin AP, Shaikh A, Asghar S, et al. An evaluation of health utility and quality-of-life in hemophilia: a systematic literature review. Presented at the annual meeting of the National Hemophilia Foundation; 3–5 October 2019; Anaheim, CA.
Chhabra A, Spurden D, Fogarty PF, et al. Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia A and B. Blood Coagul Fibrinolysis. 2020;31(3):186–92.
Article
Google Scholar
Wang C, Young G. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B. Haemophilia. 2018;24(3):414–9.
Article
CAS
Google Scholar
Buckner TW, Batt K, Quon D, et al. Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patient-reported outcome instruments in the Pain, Functional Impairment, and Quality of Life (P-FiQ) study. Eur J Haematol. 2018;100(Suppl 1):5–13.
Article
Google Scholar
Centers for Disease Control and Prevention. Hemophilia: Data & statistics on hemophilia. https://www.cdc.gov/ncbddd/hemophilia/data.html. Accessed 24 November 2020.
Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935–9.
Article
CAS
Google Scholar
O’Hara J, Khair K, McLaughlin P, et al. “Problem Joint” a more patient relevant definition for joint morbidity in haemophilia. Haemophilia. 2019;25(Suppl 1):P154.
Google Scholar
Pickard AS, Law EH, Jiang R, et al. United States valuation of EQ-5D-5L health states using an international protocol. Value Health. 2019;22(8):931–41.
Article
Google Scholar
IBM Micromedex RED BOOK. https://www.ibm.com/products/micromedex-red-book. Accessed 13 October 2020.